<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02591017</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2014-249</org_study_id>
    <nct_id>NCT02591017</nct_id>
  </id_info>
  <brief_title>Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients</brief_title>
  <acronym>ONKEMI</acronym>
  <official_title>Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      34 adult (&gt;18 years) cancer pain outpatients with Opioid base therapy because of pain and
      breakthrough pain or extreme pain on movement will be included in this prospective,
      randomized, double-blind crossover study.

      Over a period of 3 weeks patients will go through 3 treatment arms, each one lasting one
      week: Group A receives morphine drops and Placebo spray, Group B receives ketamine/chitosan
      spray nasal and Placebo drops and Group C receives morphine drops and ketamine/chitosan spray
      nasal.

      Primary endpoint is time to onset of action of intranasal ketamine compared with morphine
      drops. Secondary endpoint is the median numeric rating scale (NRS) improvement after using
      the spray or morphine or the combination of ketamine spray and morphine drops.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to onset of action of intranasal ketamine compared with morphine drops</measure>
    <time_frame>5 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to onset of action of intranasal ketamine compared with morphine drops</measure>
    <time_frame>10 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to onset of action of intranasal ketamine compared with morphine drops</measure>
    <time_frame>15 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to onset of action of intranasal ketamine compared with morphine drops</measure>
    <time_frame>20 minutes</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to onset of action of intranasal ketamine compared with morphine drops</measure>
    <time_frame>45 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median NRS improvement after using the spray or morphine or the combination of ketamine spray and morphine drops</measure>
    <time_frame>after 5, 10, 15, 20, 45 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of delivered applications of ketamine or morphine in each study arm</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total amount of fixed and reserve opioid doses increase in each study arm</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Nausea, vomiting, itching, fatigue, hallucinations, Irritation of nasal mucosa</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Cancer: Breakthrough Pain</condition>
  <condition>Cancer: Extreme Pain on Movement</condition>
  <arm_group>
    <arm_group_label>morphine drops solo and placebo spray</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>morphine 2% drops
daily fixed dose of morphine equivalents &lt; 100 mg, 0.2 mg/kg Body weight morphine drops every hour in reserve due to international Standards
daily fixed dose of morphine equivalents =/&gt; 100 mg, 15% of the fixed daily dose in morphine drops every hour in reserve due to international standards</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketamine/chitosan spray nasal and placebo drops</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5 mg ketamine all 5 minutes, maximal 4 times an hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine drops and ketamine/chitosan spray nasal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>see above</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>morphine drops solo and placebo spray</arm_group_label>
    <arm_group_label>morphine drops and ketamine/chitosan spray nasal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <arm_group_label>ketamine/chitosan spray nasal and placebo drops</arm_group_label>
    <arm_group_label>morphine drops and ketamine/chitosan spray nasal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>morphine drops solo and placebo spray</arm_group_label>
    <arm_group_label>ketamine/chitosan spray nasal and placebo drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chitosan</intervention_name>
    <arm_group_label>ketamine/chitosan spray nasal and placebo drops</arm_group_label>
    <arm_group_label>morphine drops and ketamine/chitosan spray nasal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer pain in outpatients with:

          -  Opioid based therapy due to pain

          -  Breakthrough pain or

          -  Extreme pain on movement

          -  Age &gt;= 18 years

        Exclusion Criteria:

          -  Patients unable to give written informed consent

          -  Patients unable to understand how to handle and document the use of the study
             medication

          -  Known drug allergies or intolerance to ketamine

          -  Known drug allergies or intolerance to morphine

          -  Known allergy to crustacea or chitosan

          -  Patients using snuff at a regular basis

          -  Recreational drug addiction or abuse

          -  Serious intranasal or epipharyngeal Problems (Septum wall defects, cancer)

          -  Mental/psychiatric disorder

          -  Patients with renal failure (clearance &lt; 30 ml/min)

          -  Pregnancy and breast feeding mothers

          -  Patients not understanding German

          -  Patient having arterial hypertonia with measured values &gt; 180/95
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilhelm Ruppen, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pain Relief Unit and Anaesthesiology, University Hospital Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilhelm Ruppen, PD Dr. med.</last_name>
    <phone>061 365 40 37</phone>
    <email>wruppen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Esther Seeberger, DAS</last_name>
    <phone>0613287424</phone>
    <email>esther.seeberger@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pain Relief Unit and Anaesthesiology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilhelm Ruppen, PD Dr. med.</last_name>
      <phone>0613654037</phone>
      <email>wruppen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Esther Seeberger, DAS</last_name>
      <phone>0613287424</phone>
      <email>esther.seeberger@usb.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cancer Pain</mesh_term>
    <mesh_term>Breakthrough Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Chitosan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

